Ig. Ron et al., Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer, AM J CL ONC, 22(1), 1999, pp. 35-37
Citations number
7
Categorie Soggetti
Oncology
Journal title
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
A phase II study of carboplatin and etoposide as salvage polychemotherapy i
n metastatic, infiltrating breast carcinoma was carried out with 25 multipl
y pretreated patients. Six of 25 patients (24%) had a partial response that
lasted an average of 3.5 months; of the six responders, four had undergone
either four or five previous chemotherapeutic treatments. Eight of 25 pati
ents (32%) had stable disease, and 11 (44%) manifested disease progression.
The median survival from time of entry to the salvage protocol was 8 month
s. There were treatment responses in lung, chest wall, liver, and skeleton.
The most common side effects were leukopenia (68% of 25 patients), thrombo
cytopenia (56%), anemia (40%), fever (28%), and weakness (16%). Carboplatin
combined with etoposide may be an effective and tolerable salvage regimen
in advanced breast cancer.